Ankylosing Spondylitis and Cannabis: Managing Spinal Inflammation

Understanding Ankylosing Spondylitis

• Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the spine, sacroiliac joints, and entheses
• Characteristic features include morning stiffness, inflammatory back pain, and progressive spinal fusion in severe cases
• NSAIDs are first-line therapy, but a substantial proportion of patients either fail to respond or cannot tolerate long-term NSAID use
• Biologics targeting TNF-alpha and IL-17 are effective but expensive and associated with infection risk and other adverse effects

Ankylosing spondylitis affects around 200,000 people in the UK and often begins in early adulthood, making long-term symptom management a priority for patients.

Cannabis as an Adjunct in AS

• Both THC and CBD have demonstrated anti-inflammatory and analgesic properties relevant to the inflammatory pain of AS
• CB2 receptors on immune cells involved in AS pathology — including macrophages and T-cells — are modulated by cannabinoid therapy
• Cannabis may particularly benefit patients with refractory axial pain and sleep disturbance, two hallmarks of AS
• Patient survey data from AS and axial spondyloarthropathy registries consistently show perceived benefit from cannabis use

Medical cannabis is not a disease-modifying treatment for ankylosing spondylitis, but its analgesic and anti-inflammatory properties may offer meaningful symptom relief for patients with inadequate control on standard therapies.

Accessing Cannabis for AS in the UK

• A rheumatologist or specialist pain physician is the appropriate prescriber for cannabis in ankylosing spondylitis
• Evidence of failed NSAID therapy and at least one biologic trial strengthens the clinical justification for a cannabis prescription
• NHS access remains difficult due to the absence of AS-specific clinical guidelines endorsing cannabis; private prescribing is the primary route
• NICE guidance on chronic pain supports the consideration of cannabis-based medicines when other options have been exhausted

UK patients with ankylosing spondylitis should not be deterred by the absence of AS-specific cannabis guidelines; specialist prescribers regularly treat chronic inflammatory pain conditions with cannabis-based medicines.

Integration with Physiotherapy and Exercise

• Exercise is a cornerstone of AS management; cannabis may help patients participate more effectively by reducing pain and stiffness
• Morning dosing may be particularly beneficial given the characteristic morning stiffness of AS
• Cannabis should not be used as a reason to reduce physiotherapy engagement or biologic therapy
• Shared care between the rheumatologist, pain specialist, and cannabis prescriber ensures coordinated, safe management

For ankylosing spondylitis patients living with persistent pain and stiffness, medical cannabis represents a worthwhile option to explore within a comprehensive, multidisciplinary treatment plan.